Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Submitted by admin on February 26, 2019 - 9:38am
Source: 
BioCentury
News Tags: 
Oyster Point
dry eye disease
OC-01
OC-02
Headline: 
Oyster Point raises $93M series B to bring dry eye nasal spray to FDA
snippet: 

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million Tuesday in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through an NDA submission.